<DOC>
	<DOCNO>NCT01098786</DOCNO>
	<brief_summary>This evaluate safety cell-derived A/H1N1 influenza HA vaccine healthy Japanese subject .</brief_summary>
	<brief_title>Drug Use Investigation Cell-culture Derived Influenza A ( H1N1 ) Emulsion HA Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy Japanese 1 . The person receive company 's new influenza vaccine ( swinederived A/H1N1 ) vaccination product . 2 . The person participate clinical study product company 's new influenza vaccine ( swinederived A/H1N1 ) receive investigational vaccine . The person regard subject one follow item 3 ) 6 ) appropriate receive preventive vaccination describe current package insert . 3 . The person show obvious fever . 4 . The person obviously suffer serious acute disease . 5 . The person obviously show anaphylaxis due ingredient vaccine . 6 . The person otherwise inappropriate state receive preventive vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Influenza A</keyword>
	<keyword>H1N1 subtype</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Cell culture</keyword>
</DOC>